Clinical trials: Ulcerative Colitis, open to volunteers
Inflammatory Bowel Disease, Ulcerative Colitis
Immune Regulation in Ulcerative Colitis or Crohn s Disease
This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type…
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
- Trial name
- NCT00001184
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Colitis, Ulcerative
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis.
- Trial name
- ENDEAVOUR-UC (NCT06398626)
- Testing
- Etrasimod
- Where
- 29 sites in United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC)
Multi-omics Dissection of Gut Microbiome Engraftment During FMT
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS).
- Conditions
- Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC), Metabolic Syndrome (MetS)
- Trial name
- DissEcT (NCT06992453)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Catholic University of the Sacred Heart
Colitis, Ulcerative
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years…
- Trial name
- ELEVATE-UCkids (NCT07470879)
- Testing
- Etrasimod
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease, Crohn's Disease
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT07619547
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn's Disease, Ulcerative Colitis (UC)
Online Pain Education for Crohn's Disease and Ulcerative Colitis
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic…
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- Trial name
- NCT07671313
- Testing
- Empowered Relief, Living Better with Chronic Pain
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- AMETRINE-SC (NCT07846683)
- Testing
- Afimkibart
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis (Disorder)
Objective Disease Control and Treatment Strategies in Ulcerative Colitis
This multicenter longitudinal observational cohort study aims to characterize objective disease-control trajectories, treatment adaptation, and long-term clinical outcomes among adults with ulcerative colitis receiving routine…
- Trial name
- CONTROL-UC (NCT07877636)
- Testing
- Routine Clinical Care
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Inflammatory Bowel Diseases (IBD), Crohn Disease
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refractory, structurally complicated, postoperative, perianal, pouch-related, or psychosocially complex disease.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Trial name
- DTT-IBD (NCT07877649)
- Testing
- Routine IBD Management and Advanced-Therapy Exposure
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Ulcerative Colitis
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue…
- Trial name
- HBOT-UC (NCT05987852)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 13 sites in United States
- Volunteers
- 126 people
- Sponsor
- Northwestern University
Ulcerative Colitis
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis…
- Trial name
- SUNSCAPE-1 (NCT07184996)
- Testing
- Duvakitug
- Where
- 240 sites in United States, Argentina and 23 more
- Volunteers
- 980 people
- Sponsor
- Sanofi
Colitis Ulcerative, Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT07463183
- Testing
- MK-8690
- Where
- 39 sites in United States, Canada and 9 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
IBS, Ulcerative Colitis, Active
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Conditions
- IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), Healthy Controls
- Trial name
- NCT02421705
- Testing
- Sample collection
- Where
- Belgium
- Volunteers
- 99,999,999 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Crohn Disease, Colitis, Ulcerative
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult…
- Trial name
- NCT04372108
- Testing
- Ustekinumab, Other Biologic Therapies
- Where
- United States
- Volunteers
- 1,536 people
- Sponsor
- Janssen Scientific Affairs, LLC
Ulcerative Colitis, Unspecified
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in…
- Trial name
- NCT06488625
- Testing
- Low-Dose CICR-NAM, High-Dose CICR-NAM, 0 g/d CICR-NAM (blinded)
- Where
- 25 sites in Germany
- Volunteers
- 459 people
- Sponsor
- University Hospital Schleswig-Holstein
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06764706
- Where
- 57 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- MIGHTY (NCT07071519)
- Testing
- Risankizumab
- Where
- 72 sites in United States, Belgium and 14 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Colitis, Ulcerative, Crohn Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group.
- Trial name
- NCT07483073
- Testing
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Pouchitis, UC - Ulcerative Colitis
Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)
The goal of this single-arm, prospective clinical trial is to assess the clinical efficacy and safety of oral Aeromonas sp. MTB-specific phage therapy in adult participants aged 18-70 years with pouchitis following ileal…
- Trial name
- NCT07878026
- Testing
- MTB-targeted phage therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jinling Hospital, China
Inflammatory Bowel Diseases, Crohn Disease
Validation and Clinical Impact of GLIM Criteria in Patients With Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the digestive tract that frequently lead to malnutrition.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative (UC), Malnutrition
- Trial name
- NCT07888023
- Volunteers
- 210 people
- Sponsor
- Assiut University